Conversely, for the group of genderassociated female tumors (subtypesof breast cancer and endometrioid carcinoma of the uterine corpus), activationof both pathways was a positive prognostic biomarker of OS(Fig. 2A).Interestingly, conflicting trends were observed in the prognosticsignificance of ERK1 and ERK2 pathway activation for sarcoma and thyroidcancer. This evidence concerns the gene MAPK1 and breast carcinoma.